About the Event
Parkinson’s Disease (PD) affects over 5,000,000 people worldwide, with 60,000 new cases diagnosed every year in the U.S., yet there are no effective treatments available today.
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) has developed a small molecule therapy that blocks the gateway through which Parkinson’s initiates and progresses. It works so well that in preclinical studies actuallyhalts and reverses functional loss caused by Parkinson’s.
It’s hard to understate how big this news is.
Join our webinar with Inhibikase CEO, Dr. Milton Werner to hear about the company’s remarkable progress in developing a treatment for Parkinson’s and other neurodegenerative diseases including Alzheimers.